60 Degrees Pharmaceuticals, Inc.
SXTP
$2.93
-$0.08-2.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 512.18% | 16.80% | 100.80% | 579.53% | 585.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 512.18% | 16.80% | 100.80% | 579.53% | 585.23% |
| Cost of Revenue | -306.17% | 214.06% | 721.27% | 104.26% | -169.04% |
| Gross Profit | 335.93% | -334.21% | -840.71% | -45.99% | 178.81% |
| SG&A Expenses | -5.04% | -7.50% | 144.08% | 38.72% | 445.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.67% | 37.51% | 407.23% | 52.02% | 186.57% |
| Operating Income | -9.59% | -39.22% | -431.57% | -40.08% | -176.65% |
| Income Before Tax | -0.16% | -151.76% | -24.83% | 116.48% | -22.53% |
| Income Tax Expenses | -600.00% | 200.00% | 300.00% | 0.00% | 133.33% |
| Earnings from Continuing Operations | -0.13% | -151.77% | -24.84% | 116.48% | -22.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -88.50% | -92.78% | -78.57% | 200.00% | 727.78% |
| Net Income | -1.63% | -151.63% | -25.06% | 116.56% | -20.14% |
| EBIT | -9.59% | -39.22% | -431.57% | -40.08% | -176.65% |
| EBITDA | -9.35% | -39.44% | -438.99% | -41.26% | -178.86% |
| EPS Basic | 89.64% | -110.23% | 74.89% | 102.74% | 47.84% |
| Normalized Basic EPS | 89.33% | 74.02% | 64.07% | 104.68% | 55.72% |
| EPS Diluted | 89.64% | -110.23% | 74.89% | 102.74% | 47.84% |
| Normalized Diluted EPS | 89.33% | 74.02% | 64.07% | 104.68% | 55.72% |
| Average Basic Shares Outstanding | 885.36% | 445.31% | 412.63% | 339.32% | 143.72% |
| Average Diluted Shares Outstanding | 885.36% | 445.31% | 412.63% | 339.32% | 143.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |